MYDECINE RECEIVES MANAGEMENT CEASE TRADE ORDER
VANCOUVER, British Columbia, 3 May
2024- Mydecine Innovations Group Inc. (the
"Company")
(CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that it
has received a temporary Management Cease Trade Order
("MCTO")
on April 26, 2024, under National
Policy 12-203 - Management Cease Trade Orders ("NP
12-203")
from the British Columbia Securities Commission
("BCSC")
in connection with the Company's filing of its audited annual
financial statements and MD&A for the financial year ended
December 31, 2023.
Pursuant
to the MCTO, the chief executive officer and the chief financial
officer of the Company may not trade in securities of the Company
until such time as the Company files its annual audited financial
statements for the year ended December 31,
2023, management's discussion and analysis, and related
certifications (the "Required Documents") and the BCSC revokes the
MCTO. The MCTO does not affect the ability of shareholders to trade
their securities.
The
Company's board of directors and management confirm that they are
working expeditiously to file the Required Documents and confirm
that since the Company's press release at 7:00AM May 3, 2024,
there is no other material information respecting the Company's
affairs that has not been generally disclosed.
The
audited annual financial statements for December 31, 2023 will include December 31, 2022 restated
comparatives.
Until
the Required Documents have been filed, the Company intends to
continue to satisfy the provisions of the alternative information
guidelines specified in NP 12-203 by issuing biweekly default
status reports in the form of further press releases for so long as
the Company remains in default of the financial statement filing
requirement.
This
announcement contains inside information for the purposes of
Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms
part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with
the Company's obligations under Article 17 of MAR.
On behalf of the Board of Directors
MYDECINE INNOVATIONS GROUP INC.
Joshua Bartch
Chief
Executive Officer
contact@mydecineinc.com
AQSE
Corporate Advisor
Novum
Securities Limited Tel:
+44 (0)207 399 9400
David Coffman/ George
Duxberry
About
Mydecine Innovations Group Inc.
Mydecine
Innovations Group™ is a biotechnology company developing the next
generation of innovative medications and therapies to address
mental health disorders such as nicotine addiction and
posttraumatic stress disorder (PTSD). The core strategy blends
advanced technology with an elaborate infrastructure for drug
discovery and development. Mydecine's dedicated multinational team
constantly develops new paths for breakthrough treatment solutions
in areas with considerable unmet needs. By collaborating with some
of the world's leading specialists, the Company aspires to
responsibly speed up the development of breakthrough medications to
provide patients with safer and more effective treatment solutions.
At the same time, Mydecine's approach focuses on the next
generation of psychedelic medicine by creating innovative compounds
with unmatched therapeutic potential through its clinical trial
efforts with world-class scientific and regulatory
expertise.
Learn more at:
https://www.mydecine.com/ and follow the company on Twitter,
LinkedIn, YouTube, and Instagram.
Forward-looking Information Statement
This news
release may contain certain "forward-looking statements" and
"forward-looking information" within the meaning of applicable
Canadian and United States
securities laws. When used in this news release, the words
"anticipate", "believe", "estimate", "expect", "target, "plan",
"forecast", "may", "schedule" and other similar words or
expressions identify forward-looking statements or information.
These forward-looking statements or information may relate to the
anticipated timing for the filing of the Annual Filings, and other
factors or information. Such statements represent the Company's
current views with respect to future events and are necessarily
based upon a
number of assumptions
and estimates that, while considered reasonable by the Company, are
inherently subject to significant business, economic, competitive,
political and social risks, contingencies and uncertainties. Many
factors, both known and unknown, could cause results, performance
or achievements to be materially different from the results,
performance or achievements that are or may be expressed or implied
by such forward-looking statements. The Company does not intend,
and does not assume any obligation, to update these forward-looking
statements or information to reflect changes in assumptions or
changes in circumstances or any other events affections such
statements and information other than as required by applicable
laws, rules and regulations.
